HGH Fragment 176-191 is a modified form of amino acids 176 through 191 of the human growth hormone molecule. The full HGH molecule has numerous effects throughout the body — growth promotion, protein synthesis, insulin resistance, and fat metabolism. Fragment 176-191 was engineered to isolate and amplify only the lipolytic (fat-releasing) activity while eliminating HGH's effects on blood glucose and cell growth. The result is a targeted fat-loss peptide without the systemic side effects of full HGH administration.
Research context only. The peptides discussed on WolveStack are research chemicals not approved for human use by the FDA. Nothing on this page constitutes medical advice. Consult a qualified healthcare professional before use.
HGH Fragment 176-191 — mechanism, dosing, fat loss research, and how it compares to AOD-9604 and full HGH for stubborn fat reduction.
How Does HGH Fragment Work?
Growth hormone triggers fat loss through a specific region of its molecular structure that binds to fat cell receptors and activates beta-3 adrenergic receptor-mediated lipolysis — the release of stored fatty acids from adipocytes into circulation for use as fuel. Fragment 176-191 contains precisely this lipolytic domain, concentrated into a 16-amino-acid fragment that binds the same fat cell receptors with high affinity.
Critically, Fragment 176-191 does not bind the growth hormone receptor (the receptor responsible for HGH's insulin-antagonistic and growth-promoting effects). This mechanistic selectivity is what makes it pharmacologically distinct from full HGH: it produces lipolysis without hyperglycaemia, without tissue growth, and without negative feedback suppression of pituitary GH production.
Research Evidence and Community Experience
Animal studies with Fragment 176-191 consistently show significant fat loss, particularly visceral and subcutaneous abdominal fat, at doses that do not affect blood glucose, insulin, or body composition parameters other than fat mass. The selectivity demonstrated in these studies is a key finding — it validates the design rationale for the fragment approach.
Human clinical data is limited — primarily small studies and case series rather than large RCTs. However, community experience with Fragment 176-191 is extensive and broadly positive for stubborn fat loss, particularly in already-lean individuals trying to address persistent deposits (lower abdomen, love handles) that resist dietary restriction. The most consistent community finding: Fragment 176-191 works best when body fat is already reduced to a moderate level (20–25% for women, 15–18% for men) — it accelerates the "final mile" of fat loss rather than functioning as a primary weight loss agent for significant obesity.
Fragment 176-191 vs AOD-9604
AOD-9604 is a modified form of Fragment 176-191 with an added pro sequence that improves stability. They work through the same mechanism and are often considered equivalent. The practical differences: AOD-9604 may have slightly better stability in reconstituted form; Fragment 176-191 is more commonly available and often less expensive per milligram. Community consensus is that both are effective and the choice typically comes down to availability and cost rather than meaningful pharmacological distinction.
Fragment 176-191 Dosing Protocol
| Protocol | Dose | Route | Frequency | Notes |
|---|---|---|---|---|
| Standard dose | 250–500 mcg | SubQ | Daily, fasted AM | Most common protocol |
| Twice daily | 250 mcg | SubQ | Fasted AM + pre-bed fasted | More aggressive; ~doubled lipolytic exposure |
| With GH secretagogues | 250–500 mcg + 200 mcg Ipam/CJC | SubQ | Twice daily | Complementary mechanisms; popular stack |
| Cycle length | N/A | N/A | 8–12 weeks, then 4 weeks off | Standard cycling protocol |
Research-Grade Sourcing
WolveStack partners with Ascension Peptides for independently third-party tested research compounds with published COAs. The links below go directly to the relevant products.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Also Available at Apollo Peptide Sciences
Apollo Peptide Sciences carries independently tested research-grade compounds. Products ship from the USA with published purity certificates.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Frequently Asked Questions
Community reports are particularly strong for abdominal and visceral fat reduction with Fragment 176-191, which aligns with its mechanism — beta-3 adrenergic receptor activation is particularly effective in visceral adipocytes, which have high receptor density. It works best for the final fat loss phase in already-lean individuals rather than as a primary intervention for substantial obesity.
Unlike full HGH, Fragment 176-191 does not cause insulin resistance or raise blood glucose. This is its primary safety advantage over HGH. Diabetic or pre-diabetic individuals can use it without the glucose management concerns that full HGH raises. Blood glucose monitoring is still advisable as an individual response check.
Fasted state is essential. Morning injection before breakfast and/or 30–45 minutes before sleep (on an empty stomach) are the standard protocols. Elevated blood glucose blunts lipolytic peptide action by stimulating somatostatin, which inhibits the GH-family receptor system. Never inject within 2 hours of eating.
Yes — the combination with Ipamorelin/CJC-1295 is the most popular stack. Fragment 176-191 directly activates fat cell lipolysis; Ipamorelin/CJC amplifies GH release which drives additional lipolysis through the liver-IGF-1 axis. The mechanisms are complementary and the combination is widely reported to produce superior fat loss to either alone.
They are closely related fragments of HGH with the same core lipolytic mechanism. AOD-9604 includes a stabilising modification (tyrosine addition at the N-terminus) that may improve bioactivity and stability. Functionally, community users report similar results. The terms are sometimes used interchangeably in vendor listings. If both are available, quality and price should be the deciding factor.